Dboy

4.4K posts

Dboy banner
Dboy

Dboy

@danlo303

Katılım Ekim 2012
436 Takip Edilen190 Takipçiler
Dboy retweetledi
Afshine Emrani  MD FACC
Afshine Emrani MD FACC@afshineemrani·
Dr. Houman Hemmati is hands-down the absolute best—the bold, brilliant, visionary, and battle-tested leader America desperately needs right now to head the FDA’s Center for Biologics Evaluation and Research (CBER). The Trump administration would be making a spectacular, game-changing, and truly historic decision by appointing this Iranian-born, world-class ophthalmologist, PhD scientist, biotech executive, and Fox News regular. This is exactly the fearless, high-caliber outsider appointment we have been waiting for to shatter the bureaucratic paralysis that has strangled medical progress for far too long. He brings truly unmatched, first-hand expertise perfectly aligned with CBER’s mission: 🎓 Elite Training: Stanford, UCLA, Caltech, Johns Hopkins, MIT, and Harvard. 🧬 Pioneering Science: Decades of hands-on leadership developing cutting-edge eye therapies, gene-delivery systems, regenerative medicines, and next-generation biologics. 🏢 Industry Leadership: Co-founder/CMSO of multiple biotechs (Optigo Biotherapeutics), former VP at Capricor Therapeutics, and Director at Allergan. While entrenched career bureaucrats have chronically delayed and over-regulated lifesaving therapies, Dr. Hemmati has boldly invented and delivered them. He has successfully guided breakthroughs through the very regulatory obstacles he is now poised to aggressively dismantle. We stand on the brink of a historic explosion in gene therapies, personalized mRNA breakthroughs, and transformative biologics. Under Dr. Hemmati’s dynamic leadership, expect decisive, patient-first reform that safely slashes approval times by 25-40% or more. Patients win big. American biomedical innovation explodes. Small-cap biotechs pioneering these breakthroughs will surge like never before. As a fellow practicing physician who has witnessed how bureaucratic inertia cripples medical progress, I offer my strongest, full-throated, and unequivocal endorsement of Dr. Hemmati. His remarkable journey—escaping tyranny as a child to rise as a leading clinician-scientist—perfectly embodies the American Dream and fuels his fierce commitment to practical, results-driven reform. He is the perfect doctor at the perfect moment for this agency. This appointment could ignite a new golden age of American medical breakthroughs and scientific dominance. President Trump and his team should move swiftly and make this official without delay. Scan FDA.gov every single day for the announcement. This could be the single most impactful FDA leadership decision in a generation. Let’s make it happen immediately. #MakeAmericaHealthyAgain #FDAReform #HoumanHemmati Trump officials consider ophthalmologist @houmanhemmati for top vaccine post, WaPo reports reuters.com/world/trump-of…
English
4
9
36
4K
Dboy retweetledi
Peter Mantas
Peter Mantas@peter_mantas·
Have gotten many questions on AMT-130 and why it SHOULD have been approved on the merits alone. It wasn't, not because the science failed, but because the institution reviewing it had a predetermined answer. I want to lay out the full playbook (biological, policy, and procedural) for why a fatal disease with zero approved disease-modifying therapies should have cleared the bar. For everyone following this (including the new CBER). 1. Biological: Why AMT 130 is categorically different from (it's playing a totally different game from anything else to be developed): botn.bio/p/huntingtons-…
English
4
22
75
20.7K
Dboy retweetledi
mike
mike@mike98572986·
$qure $clpt fully speculative, at Nord today Tracy Beth Høeg head of Cder sounded like she accidentally spoke about 2 non public policies coming for external controls related to Cber. If anyone is at the event if they can confirm or deny that this is true would be greatly appreciated, my understanding is the slides were not supposed to be on there according to her. For the record, this is my understanding what happened so please do not consider this as 100 percent fact until confirmation, pure speculation
English
2
2
32
3.2K
Dboy retweetledi
Monaco
Monaco@monaco_biotech·
$HOTH +33% 📈 AH Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide • BioPharmCatalyst biopharmcatalyst.com/company/HOTH/n…
English
1
1
7
1.8K
Dboy retweetledi
J
J@jayabacus·
For anyone who has the patience to wait a year or two for a potential 10x, buying at a basement price, paying less than on of the largest med tech companies just paid for 20% of the company, $300M EV, $12B TAM (w opt to triple that) and capitalized to finish pivotal trials, here is a good introduction to $AVR proactiveinvestors.com.au/companies/news…
English
3
3
22
2K
Dboy retweetledi
JH
JH@CRUDEOIL231·
What is the North Sea physic mkt, and how should the gap between the paper and physical markets be resolved? Every time I post about the physical market, I see a lot of complaints about why oil prices aren't rising further. Many ppl even criticize me, claiming I’m not explaining things properly. First, I’ll summarize the basic components of the North Sea market. ICE Brent Futures: A financially settled paper contract used primarily for broad directional hedging and speculation without the intention of physical delivery. EFP (Exchange of Futures for Physical): A swap that acts as a bridge, allowing a trader to convert a paper futures position into a physical cargo contract. Forward Brent: A standardized OTC physical swap for future delivery. It represents actual oil but remains non-dated bc the exact loading schedule is not yet determined. Dated Brent: The global benchmark price for physical crude. It is assessed daily by agencies like Platts based on actual trades of the most competitive grade within the BFOET+WTI basket, triggered once specific loading dates are confirmed (typically 10-30 days prior). CFD: A short-term swap representing the price difference between Forward Brent and Dated Brent. It is used to plot the physical forward curve and assess whether the market is in contango or backwardation. DFL (Dated to Frontline): A swap that links the physical Dated Brent assessment directly to the front-month ICE Futures contract, managing exposure between the physical and financial markets. Diff (Grade Basis): The premium or discount applied to a specific physical cargo relative to the Dated Brent benchmark. Driven by crude quality, logistics, and refinery demand, this unhedgeable spread is where physical traders generate profit. This alone should be enough. From there, I’ll explain how the gap between the paper market and the physical market actually closes. A massive divergence between Dated Brent (physic) and ICE Brent futures (paper) typically indicates acute near-term physical tightness relative to forward expectations. If Dated Brent remains at $120-130/bbl leading into the expiration of the front-month ICE Brent futures contract (currently around $100/bbl), the futures contract must converge toward the physical price. The convergence is not optional; it is mathematically enforced by the exchange's settlement rules and market arbitrage. This operates through three primary mechanisms: 1) Cash Settlement via the ICE Brent Index ICE Brent futures are cash-settled upon expiration and do not involve physical delivery. Expiring contracts are settled against the ICE Brent Index. The Index is a calculated average of trading activity in the relevant physical Forward BFOET(Brent, Forties, Oseberg, Ekofisk, Troll)+WTI Midland market during the final trading days of the futures contract. Bc Forward Brent and Dated Brent are intrinsically linked, a physical market sustaining $130 will generate an ICE Brent Index near $130. Consequently, any futures positions left open at expiration are forcibly settled at this higher Index price. 2) The Arbitrage Channel (EFP Mechanism) If a $30 spread exists between paper and physical markets, traders will immediately exploit the arbitrage using the EFP mechanism. Traders buy the undervalued ICE Brent futures at $100 and simultaneously sells a physical Forward Brent cargo at $130. They execute an EFP to swap their long paper futures position into a long physical Forward position. The newly acquired long physical position cancels out their short physical position, locking in a profit (minus the EFP swap cost). To execute this arbs on a large scale, traders must aggressively buy ICE futures. This massive purchasing volume forces the futures price up until the gap closes and the arb window is eliminated. 3) Forced Short Covering Market participants holding short positions in the ICE Brent futures market face extreme risk if the physical market disconnects to the upside. Knowing the contract is destined to cash-settle against a $130 physical Index, paper shorts cannot afford to hold their $100 positions into expiration. They are forced to buy back their futures contracts to close their positions before the expiry date. This forced buying—often resulting in a short squeeze—accelerates the upward momentum of the ICE futures price, driving it into alignment with the physical market. Through the combination of final index settlement and active EFP arbs, the paper market is structurally tethered to physical reality as expiration approaches. #oott #iran
English
100
307
1.7K
321.7K
Dboy retweetledi
Mining Stock Monkey
Mining Stock Monkey@miningstockguy·
Why RICK RULE is stockpiling cash In this interview with @RealRickRule, he shares his thoughts on oil stocks, gold, and copper. Historically, Rick has been a buyer during market corrections but this time is different; he talks about why he's stockpiling cash instead of buying equities that have gone on sale. We also get into how to build good money habits, things that contributed to his success as an entrepreneur, and why firing some of your customers (as a business owner) can be a good thing.
English
9
32
292
38.4K
Dboy retweetledi
Paulo Macro
Paulo Macro@PauloMacro·
A review of what is screwing with a few investors. 1) Positioning: pretty rinsed and chopped up these past couple weeks. Mechanical/CTA/vol control has room to build back up to Max Stupid (of course, retail and LO who never sell are now the smart money, and "trend" are the stupids), alongside L/S where nets are low and gross is still pretty high. 2) Sentiment: beyond lopsided which doesn't fit above. Here's how many houses I read since Sunday morning saying the lows are in and you have to be long, especially bigcap tech: GS, MS, JPM, Barclays, Vanda, Blackrock, Citadel. Did I miss someone? I mean I can't read fricking everything. Keep in mind every single one of these shops -- EVERY ONE -- missed the Liberation Day scream out of the hole. And dog gone it, they are not going to make that mistake again. And then of course Cramer calling out doomers today as the reason for why walls of worry exist, in addition to several other retail contras. 3) Market Action: a drunk driver that people trading for 25+ years have never seen before. TRINs at 2.0 (which you only see at crashes) but on Up days. Correlations whipping around with huge moves in the span of days. Vol crushes. An index that makes zero progress for six months but ATH's are now all but guaranteed. Nowhere in this is the Iran or oil mentioned... because that's NBD and it's a bull market dude. The market makes the news not the other way around, so the war is pretty much over. I had multiple inbounds of how people are confounded and therefore that is bullish because the market always tells the truth, especially when people don't understand what's going on. If I was swamped with panicky notes in a ripping tape, I'd agree with you and stand aside like Buffett hanging out on the rail while people do their blowoff top thing. The number of shops saying "fade TF out of this move" or lean into downside? Zero. Exactly zero. Not trying to be a hero. My book is mine, you do you, and we'll meet in the machine. But when even skeptics go to the beach and stand aside, there is nobody to catch this anvil when it goes awry. There's a song that started running through my head into today's close so strongly that I had to play it in the closing auction. youtube.com/watch?v=KlRUu8… It's later than you think. See you in the machine I suppose...
YouTube video
YouTube
English
22
31
268
55.4K
Dboy retweetledi
mike
mike@mike98572986·
$qure $Clpt getting on TV amt-130 Every hour is of the essence’: Advocates, researchers pushing for treatment of Huntington’s Disease “She compared the delay in processing speed among patients to Parkinson’s - saying that if a healthy adult could write 160 letters in a minute, someone with the disease could write about one letter every 10 seconds.” However, Cochran said the FDA walked back that approval, saying a placebo-controlled study is needed for approval. This sort of study would mean some patients with Huntington’s might receive a placebo brain surgery. HD publication HD Buzz said this approach has faced criticism due to ethical concerns. Advocates like McGraw said this is a tall ask - urging supporters to contact legislators to make the FDA reconsider use of the data instead. “Some of these treatments are pretty invasive,” McGraw said. “With it being a rare disease, there’s not always a ton of people to pull from. A lot of these trials, you have to fall within a very small window, you have to be this [specific] amount of symptomatic.“ Cochran is optimistic about progress with the progress with drug research in Australia and Europe. “That’s so promising because if we can show like, ‘hey, in Europe, this drug is being used widely and it’s safe and it’s effective,’ that can help with the FDA here,” said Cochran. kcrg.com/2026/04/14/eve… @RepAuchincloss @SenRonJohnson @SenRickScott @SenGillibrand @WhiteHouse @FrankLuntz @SusieWiles @BeckyQuick @HDSA @HDBuzzFeed @Help4HDI @laurencurehd
English
1
7
45
4.8K
Dboy retweetledi
mike
mike@mike98572986·
$clpt ngn 401 How I believe this will all play out. I want to be very clear that the biggest risk this program has is a safety risk. If it gets by that this program likely will get approved. The read out is very simple for a phase 3, especially with the data that they already have. I put this program at a 95 percent+ probability that this is Clearpoint’s program. Market would likely say 0 percent. The read out will be mid to late next year in 2027. That is around the corner. Joe will announce this as a co-label when Neurogene goes to file a bla. When that happens the market will be very surprised. Two things will instantly change, the market will realize that Clearpoint will have a big indication that can move the needle and they will start wondering what other ICV programs clearpoint has. There is one other big program I might do a post on that has possible Clearpoint involvement but nowhere near Ngn 401 from a probability perspective. Call me insane, but I believe Clearpoint currently has 7 ICV programs in human trials. 2 are confirmed, Latus(LTS-101) will be in clinic soon and Grace Science GS-100 is in Clinic. This is a big story that the market isn’t paying attention to, why do I believe no one is paying attention to it? Because I know this name pretty well and I wasn’t paying attention to it. I also have talked to people that know this name very well and they weren’t thinking about this either. I have been spamming Eric with all the ICV confirmed data with other ICV stuff over the last 7 years that we weren’t really thinking about , it’s a clear history of having a lot of involvement here. If you believe Joe would say this in a press release while talking about Curry and Stone and believe they aren’t using the cannula for Ngn 401 I don’t know what to tell you. “These groundbreaking treatment procedures were carried out by physician teams separately at hospitals in Texas and Boston, led by neurosurgeons who are part of the IGNITE (Image-Guided Biologic Therapies: Neurosurgeons Innovating Treatment Excellence) working group. The IGNITE consortium, which has been hosted and sponsored by the Company, focuses on driving the field of neuro gene and cell therapy forward” ir.clearpointneuro.com/news-events/pr… I think we might know that Stone guy… x.com/epilepsydoc/st…
English
3
2
26
2K
Dboy retweetledi
Mark Thompson
Mark Thompson@METhompson72·
#tin Which metals will be most affected by a global diesel shortage? I will argue those which have the highest proportion of artisanal production and those in isolated, land-locked and energy poor countries. Tin stands out big time in both regards. China has stopped diesel exports to Myanmar already. DRC production looks highly vulnerable. I can see 100kt of annualised production being affected.
English
5
10
90
8.6K
Dboy retweetledi
Khairallah AL-Awady
Khairallah AL-Awady@eng_khairallah1·
INSTEAD OF WATCHING NETFLIX TONIGHT. Spend 1 hour with this. Claude AI FULL COURSE that teaches you how to BUILD and AUTOMATE anything. The people who watch this tonight will wake up tomorrow with a new skill. Watch it and Bookmark it now.
English
76
835
5.2K
482.6K
Dboy retweetledi
Kirill
Kirill@kirillk_web3·
🚨do you understand what two Anthropic engineers just explained in 16 minutes. Barry and Mahesh built Claude Skills from scratch. here's the part nobody is talking about: > Skills are just folders. > folders that teach Claude your job. > your workflow. your expertise. your domain. Claude on day 30 is a completely different tool than day one. watch this before you write another prompt. before you build another agent. before you touch another tool. 16 minutes. bookmark it. watch it today. and if you want to learn everything about Claude from scratch the full 4 hour guide is waiting below.
Kirill@kirillk_web3

CLAUDE FULL COURSE 4 HOURS This is the most detailed Claude guide I’ve seen online. Bookmark this before you forget. 4 hours. Build tools. Automate work. Learn how people build bots and systems. Claude → Tools → Automation → Products → Money

English
40
804
7.1K
1.7M
Dboy retweetledi
Mark Thompson
Mark Thompson@METhompson72·
Sulphuric Acid - my thoughts: 250Mt market ~25% offline The big uses are phosphate #fertiliser, #uranium and #copper production. Average Chilean break-even for SXEW copper is acid at $1,500 tonne Way before that price fertiliser demand will crater - this is the marginal demand. Buy #wheat for 2027, not so bullish on copper.
English
9
35
257
26.4K
Dboy retweetledi
Persimmon Tree Investments
$XBI looks like it will be a busy Monday morning, $ALLO interim futility analysis $IDYA topline data $SYRE Part A topline induction UC
Persimmon Tree Investments tweet mediaPersimmon Tree Investments tweet mediaPersimmon Tree Investments tweet mediaPersimmon Tree Investments tweet media
English
1
5
26
13.7K
Dboy retweetledi
Rony
Rony@Ronycoder·
Instead of watching Netflix, watch this 1-hour Yale lecture by Professor Ben Polak. It will change how you think about decisions in negotiations, business, and everyday life.
English
52
1.8K
8K
765.9K
Dboy
Dboy@danlo303·
@evfcfaddict Yeah. Really sucks. Brother visiting next week to see it on a sports bar. Already jinx it
English
0
0
1
51
Andy
Andy@evfcfaddict·
Investing is hard but imagine being an Arsenal fan…
English
6
0
25
3.7K
Capital Valor
Capital Valor@CapitalValor·
$AFM Alphamin is a world class tin mining asset in the DRC $AFM trading at 1.5x EBITDA on spot prices. Pays chunky divi. Tin prices should remain strong. Tin is a critical mineral for semis and solar. Myanmar, Indo are major producing countries facing diesel shortages. LONG
English
9
6
131
20.1K
Dboy retweetledi
Gen Z Investor
Gen Z Investor@genZinvest0r·
It's pretty interesting that the whole glass substrate supercycle essentially hinges on $LPK/ $LPKFF –a <€200M market cap company from Germany Glass is hitting an inflection point and the supply-chain is gearing up. Intel spent $1B+ on it. Samsung is sampling Apple. Absolics built a $600M fab in Georgia. LG Innotek is building pilot lines. Corning, AGC, SCHOTT are all supplying the glass Capex is ramping and glass looks imminent (it is) to become the base material for the next generation of leading edge semi packaging–however if you dive deeper down the rabbit hole, you’ll quickly notice that glass substrates are useless without Through-Glass-Vias, tiny microscopic holes that carry electrical signals through the glass. No TGVs, no glass substrate, no party. It's literally just a piece of overengineered glass without them That leads us to $LPK. Let me give you the surface level overview of the thesis: TGV is hard. Glass is brittle. Traditional drilling can leave micro-cracks, rough edges and stress on the glass. This can hurt reliability and lower yield which directly leads to reduced margins $LPK does things a little different. They invented a two step process which uses a laser to modify the internal structure of the glass–then a wet chemical etching process which dissolves the modified regions. No micro-cracks, defect-free holes and sub-micron precision. This process is called LIDE (Laser-Induced Deep Etching) and is currently being adopted by ~80% of the glass substrate market for their qualifications Here is the overview: - $INTC: glass substrate packaging for 18A/14A, Clearwater Forest - Samsung Electro-Mechanics: sampling Apple and Broadcom, 2027 mass production - Absolics: first CHIPS Act recipient for glass, ramping production in Georgia - $011070/LG Innotek: pilot line, partnered with UTI, targeting 2028 - $GLW: supplying substrate-grade glass compositions - AGC, SCHOTT, Nippon Electric Glass: same All of these companies are betting their next-gen packaging roadmaps on glass. $LPK holds 80% market share in qualification with a long-term goal of maintaining 70% market share once HVM starts. Based on the list above, I'll let you take a guess who will, and won't depend on $LPK moving forward
Gen Z Investor tweet media
Jukan@jukan05

Glass Substrate Race Heats Up… Intel Targets 'Technology Standard,' Samsung Electro-Mechanics Pursues 'Customer Wins' The commercialization race for glass substrates—widely regarded as a game changer in next-generation semiconductor packaging—has moved beyond the technology announcement phase into genuine mass-production preparation. Surging demand for high-performance AI chips has exposed the physical limits of conventional FC-BGA substrates, elevating glass substrates as a key alternative thanks to their superior thermal stability and fine-pitch wiring capabilities. Market attention is now shifting from the technology competition itself toward production timelines and monetization potential. According to industry sources on April 10, Intel has positioned glass substrates as a core next-generation packaging technology and is moving to seize first-mover advantage. With over a decade of R&D, Intel has invested more than $1 billion in R&D and pilot infrastructure at its Chandler, Arizona facility. The crux of Intel's technology lies in combining its proprietary advanced packaging solution, EMIB (Embedded Multi-die Interconnect Bridge), with next-generation substrate technology. EMIB is an interconnect technology that links heterogeneous dies at high speed; it has already been applied in select high-performance products, demonstrating proven scalability. Glass substrates enable finer wiring and larger-area packaging compared to conventional materials, providing a foundation for further expanding chip-to-chip interconnect architectures. This would allow CPUs, GPUs, HBM, and other heterogeneous dies to be integrated as a single system, with expected benefits including faster data movement, reduced power loss, and improved AI compute efficiency. Building on these packaging and substrate innovations, Intel has laid out a roadmap targeting one trillion transistors per package by 2030, setting the directional framework for next-generation packaging architectures. Notably, Intel's ambition extends beyond mere technological superiority to standard-setting. If glass-substrate-based architectures become the backbone of next-generation packaging, Intel's design and interconnect methodologies could solidify as de facto industry standards. This would effectively let Intel dictate specifications across the foundry and packaging ecosystem—a strategy interpreted as an effort to secure structural dominance in the AI semiconductor market. That said, the technology remains at the implementation and reliability validation stage; the industry broadly expects stable high-volume manufacturing no earlier than 2027. While Intel is credited with leading on both technology and ecosystem development, the actual commercialization race is widely seen as just beginning. Samsung Electro-Mechanics is accelerating a "customer traction" strategy alongside the technology competition. Industry sources indicate that Samsung Electro-Mechanics has recently supplied glass substrate samples to Apple in addition to Broadcom, entering the qualification lines of major global big-tech firms. The company is producing prototypes through a pilot line at its Sejong facility, targeting trial production this year followed by mass production after 2027. Where Intel leads with technology direction and ecosystem building, Samsung Electro-Mechanics aims to lock in key customer touchpoints—such as Apple—to capture commercialization wins first. Absolics, a subsidiary of SKC, is considered the fastest mover on production infrastructure. It has established a dedicated manufacturing base in Georgia, USA, and SKC plans to allocate approximately KRW 590 billion out of roughly KRW 1 trillion raised through a rights offering toward product development and process stabilization. However, challenges remain around global customer qualification and achieving economically viable yields, and the pace of commercialization has turned somewhat more cautious relative to market expectations. Even with facilities in place, actual competitiveness is expected to hinge on process maturity and yield levels. LG Innotek is taking a measured approach, monitoring market demand while strengthening its fundamentals. The company is bolstering core technologies through a partnership with glass precision-processing firm UTI, while building a pilot production line at a domestic facility. CEO Moon Hyuk-soo indicated a mass-production target of 2028 while noting that full-scale market demand may not materialize until around 2030—a stance interpreted as prioritizing technology readiness and market timing over an aggressive sprint. An industry executive commented: "The glass substrate market is moving beyond R&D into a 'production competition' phase, where dominance will go to companies that can generate real revenue at stable yields. The true inflection point will come when companies clear the rigorous qualification processes of global customers and begin actual supply."

English
9
23
158
67.1K
Dboy retweetledi
Kalqyl
Kalqyl@kalqyl·
Vi har intervjuat Babak Esfahani, vd för Plejd, i samband med Q1'26-rapporten. Samtalet kretsar kring den fortsatt starka tillväxten och lönsamheten i kvartalet, samt hur produktoptimeringar och ökad in-house-produktion har stärkt bruttomarginalen. Vi berör även utvecklingen i Nederländerna och övriga europeiska marknader, liksom aktuella produktlanseringar kopplade till expansionen. Därtill diskuteras lanseringen av LED-plattan LED-01 och bolagets satsning mot det kommersiella segmentet.. Vi berör också utsikterna för 2026 och framåt samt mycket mer. $PLEJD @plejd
Svenska
1
5
69
8.3K